BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 1
• 2
• 3
• 4
• 5
• 6
• 7
• 8
• 9
• 10
• 11
• 12
• 13
• 14
• 15
• 16
• 17
• 18
• 19
• 20
• 21
• 22
• 23
• 24
• 25
• 26
• 27
• 28
• 29
• 30

• 

  Business

  Q&A: Foghorn SVP Expounds on “Tremendous Opportunity” in Chromatin Remodeling

  BioSpace caught up Foghorn Therapeutics’ Steven Bellon, Ph.D., SVP, drug discovery, shortly before he chaired a panel on new epigenetic developments at the AACR Annual Meeting 2021.

  April 20, 2021

   · 

  4 min read

   · 

  Gail Dutton
• 

  Drug Development

  Humanigen’s Cytokine Storm Control Drug Shows Positive Results in CAR-T Trial

  Humanigen reported positive data from its Phase Ib ZUMA-19 trial of lenzilumab in patients treated with CAR-T in diffuse large B-cell lymphoma (DLBCL).

  April 20, 2021

   · 

  3 min read

   · 

  Mark Terry
• 

  Pharm Country

  An Update on the J&J COVID-19 Vaccine Pause: What We Know So Far

  This is an update on what is known about the clots and what the likely course of action is going to be.

  April 20, 2021

   · 

  4 min read

   · 

  Mark Terry
• 

  Business

  Money on the Move: April 14-20

  Investment funds continue springing up into life sciences companies across the globe. Here’s where the money’s being planted this week.

  April 20, 2021

   · 

  4 min read

   · 

  Kate Goodwin
• 

  FDA

  Amgen Awarded Breakthrough Designation for Acquired Cancer Antibody Drug

  Amgen announced the U.S. FDA awarded Breakthrough Therapy Designation to the bemarituzumab as a first-line treatment for certain types of gastric cancer.

  April 20, 2021

   · 

  3 min read

   · 

  Alex Keown
• 

  The Column Group Debuts $824 Million Biotech Crossover Fund

  Science-driven VC firm The Column Group set up its debut crossover fund with an oversubscribed $824 million to start.

  April 20, 2021

   · 

  2 min read

   · 

  Kate Goodwin
• 

  Drug Development

  KalVista’s Hereditary Angioedema Trial On Hold as FDA Requests Additional Data

  The agency is requesting additional information and analysis of preclinical studies regarding KVD824 before giving the go-ahead to the Phase II trial.

  April 20, 2021

   · 

  3 min read

   · 

  Brandon May
• 

  Drug Development

  When Will Lecanemab be Available to Alzheimer’s Patients?

  An optimistic trend reported from the experimental drug lecanemab (BAN2401) clinical trials broaches the question of when the joint asset of Eisai Co., Ltd. and Biogen Inc. will hit the market.

  April 20, 2021

   · 

  2 min read

   · 

  Ava Barnes
• 

  Drug Development

  COVID-19 News: Researchers Discover a New Variant, Antiviral Shows Promise in Hamsters and More

  Please check out the biopharma industry’s COVID-19 stories that are trending for April 20, 2021.

  April 20, 2021

   · 

  4 min read

   · 

  BioSpace Editorial Staff
• 

  Business

  Vertex Drops $900 Million to Expand Partnership with CRISPR Therapeutics

  Under the terms of the expanded deal, Vertex will be responsible for 60% of the costs of developing, manufacturing and commercializing CTX001 with support from CRISPR Therapeutics, and will receive 60% of profits from global sales.

  April 20, 2021

   · 

  4 min read

   · 

  Mark Terry